scholarly journals Human Immature Dental Pulp Stem Cells (hIDPSCs), Their Application to Cell Therapy and Bioengineering: An Analysis by Systematic Revision of the Last Decade of Literature

2013 ◽  
Vol 296 (12) ◽  
pp. 1923-1928 ◽  
Author(s):  
Priscilla Vianna De Souza ◽  
Fabiana Bucholdz Teixeira Alves ◽  
Cristina Lucia Sant'Ana Costa Ayub ◽  
Maria Albertina De Miranda Soares ◽  
Jose Rosa Gomes
2019 ◽  
Vol 10 ◽  
Author(s):  
Xiaoyan Lan ◽  
Zhengwu Sun ◽  
Chengyan Chu ◽  
Johannes Boltze ◽  
Shen Li

Stem Cells ◽  
2016 ◽  
Vol 35 (1) ◽  
pp. 61-67 ◽  
Author(s):  
Ben Mead ◽  
Ann Logan ◽  
Martin Berry ◽  
Wendy Leadbeater ◽  
Ben A. Scheven

Biomedicines ◽  
2020 ◽  
Vol 8 (11) ◽  
pp. 483
Author(s):  
Jon Luzuriaga ◽  
Jon Irurzun ◽  
Igor Irastorza ◽  
Fernando Unda ◽  
Gaskon Ibarretxe ◽  
...  

The generation of vasculature is one of the most important challenges in tissue engineering and regeneration. Human dental pulp stem cells (hDPSCs) are some of the most promising stem cell types to induce vasculogenesis and angiogenesis as they not only secrete vascular endothelial growth factor (VEGF) but can also differentiate in vitro into both endotheliocytes and pericytes in serum-free culture media. Moreover, hDPSCs can generate complete blood vessels containing both endothelial and mural layers in vivo, upon transplantation into the adult brain. However, many of the serum free media employed for the growth of hDPSCs contain supplements of an undisclosed composition. This generates uncertainty as to which of its precise components are necessary and which are dispensable for the vascular differentiation of hDPSCs, and also hinders the transfer of basic research findings to clinical cell therapy. In this work, we designed and tested new endothelial differentiation media with a fully defined composition using standard basal culture media supplemented with a mixture of B27, heparin and growth factors, including VEGF-A165 at different concentrations. We also optimized an in vitro Matrigel assay to characterize both the ability of hDPSCs to differentiate to vascular cells and their capacity to generate vascular tubules in 3D cultures. The description of a fully defined serum-free culture medium for the induction of vasculogenesis using human adult stem cells highlights its potential as a relevant innovation for tissue engineering applications. In conclusion, we achieved efficient vasculogenesis starting from hDPSCs using serum-free culture media with a fully defined composition, which is applicable for human cell therapy purposes.


2019 ◽  
Vol 45 (2) ◽  
pp. 144-149 ◽  
Author(s):  
Gastón Meza ◽  
Denisse Urrejola ◽  
Nicole Saint Jean ◽  
Carolina Inostroza ◽  
Valentina López ◽  
...  

2017 ◽  
Vol 14 (7) ◽  
Author(s):  
Junjun Liu ◽  
Zhi Liu ◽  
Chunyan Wang ◽  
Fang Yu ◽  
Wenping Cai ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yuko Nitahara-Kasahara ◽  
Mutsuki Kuraoka ◽  
Posadas Herrera Guillermo ◽  
Hiromi Hayashita-Kinoh ◽  
Yasunobu Maruoka ◽  
...  

Abstract Background Duchenne muscular dystrophy (DMD) is an inherited progressive disorder that causes skeletal and cardiac muscle deterioration with chronic inflammation. Dental pulp stem cells (DPSCs) are attractive candidates for cell-based strategies for DMD because of their immunosuppressive properties. Therefore, we hypothesized that systemic treatment with DPSCs might show therapeutic benefits as an anti-inflammatory therapy. Methods To investigate the potential benefits of DPSC transplantation for DMD, we examined disease progression in a DMD animal model, mdx mice, by comparing them with different systemic treatment conditions. The DPSC-treated model, a canine X-linked muscular dystrophy model in Japan (CXMDJ), which has a severe phenotype similar to that of DMD patients, also underwent comprehensive analysis, including histopathological findings, muscle function, and locomotor activity. Results We demonstrated a therapeutic strategy for long-term functional recovery in DMD using repeated DPSC administration. DPSC-treated mdx mice and CXMDJ showed no serious adverse events. MRI findings and muscle histology suggested that DPSC treatment downregulated severe inflammation in DMD muscles and demonstrated a milder phenotype after DPSC treatment. DPSC-treated models showed increased recovery in grip-hand strength and improved tetanic force and home cage activity. Interestingly, maintenance of long-term running capability and stabilized cardiac function was also observed in 1-year-old DPSC-treated CXMDJ. Conclusions We developed a novel strategy for the safe and effective transplantation of DPSCs for DMD recovery, which included repeated systemic injection to regulate inflammation at a young age. This is the first report on the efficacy of a systemic DPSC treatment, from which we can propose that DPSCs may play an important role in delaying the DMD disease phenotype.


2021 ◽  
Vol 6 (9) ◽  
pp. 2742-2751
Author(s):  
Myung Chul Lee ◽  
Hoon Seonwoo ◽  
Kyoung Je Jang ◽  
Shambhavi Pandey ◽  
Jaewoon Lim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document